Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

TheraCIM (nimotuzumab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Biocon, Daiichi Sankyo, Oncoscience

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

asandeutertinib (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

HIF1A overexpression	Squamous Cell Carcinoma of Head and Neck	HIF1A overexpression	Squamous Cell Carcinoma of Head and Neck	nimotuzumab Sensitive: C3 – Early Trials nimotuzumab Sensitive : C3	nimotuzumab Sensitive: C3 – Early Trials nimotuzumab Sensitive : C3
CD44 underexpression	Squamous Cell Carcinoma of Head and Neck	CD44 underexpression	Squamous Cell Carcinoma of Head and Neck	nimotuzumab Sensitive: C3 – Early Trials nimotuzumab Sensitive : C3	nimotuzumab Sensitive: C3 – Early Trials nimotuzumab Sensitive : C3
KRAS wild-type	Pancreatic Cancer	KRAS wild-type	Pancreatic Cancer	nimotuzumab Sensitive: C3 – Early Trials nimotuzumab Sensitive : C3	nimotuzumab Sensitive: C3 – Early Trials nimotuzumab Sensitive : C3
PD-L1 overexpression	Oral Cancer	PD-L1 overexpression	Oral Cancer	nivolumab + nimotuzumab Sensitive: C4 – Case Studies nivolumab + nimotuzumab Sensitive : C4	nivolumab + nimotuzumab Sensitive: C4 – Case Studies nivolumab + nimotuzumab Sensitive : C4
EGFRvIII expression	Glioblastoma	EGFRvIII expression	Glioblastoma	nimotuzumab Sensitive: D – Preclinical nimotuzumab Sensitive : D	nimotuzumab Sensitive: D – Preclinical nimotuzumab Sensitive : D
EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	nimotuzumab Sensitive: D – Preclinical nimotuzumab Sensitive : D	nimotuzumab Sensitive: D – Preclinical nimotuzumab Sensitive : D